公开(公告)号：US20190091146A1

公开(公告)日：2019-03-28

申请号：US16200127

申请日：2018-11-26

Applicant: Biogen MA Inc.

Inventor： Peter Zawaneh ,  Shyam B. Karki ,  Michael Kaufman ,  Cheuk-Yui Leung ,  Jinquan Dong ,  Ernest Quan ,  Kalyan Vasudevan

IPC: A61K9/00 ,  A61K9/20 ,  A61K9/28 ,  A61K9/50 ,  A61K9/14 ,  A61K9/48 ,  A61K31/22

Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.

公开(公告)号：US10172794B2

公开(公告)日：2019-01-08

申请号：US15102306

申请日：2014-12-12

Applicant: Biogen MA Inc.

Inventor： Peter Zawaneh ,  Shyam B. Karki ,  Michael Kaufman ,  Cheuk-Yui Leung ,  Jinquan Dong ,  Ernest Quan ,  Kalyan Vasudevan

IPC: A61K9/00 ,  A61K9/20 ,  A61K9/28 ,  A61K31/225 ,  A61P25/00 ,  A61K9/48 ,  A61K9/50 ,  A61K31/22 ,  A61K9/14

Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.